Answers are grounded in this paper and cite their sources.
SUMMARY Aprotinin is a serine protease inhibitor that binds to human serine proteases with various affinities. This small protein has profound effects on the systemic inflammatory response syndrome induced by cardiopulmonary bypass. The intersecting pathways of complement, cytokines, coagulation, fibrinolytic, and kinin‐kallikrein systems all converge with tremendous amplification and potentially damaging effects to the patient. Aprotinin exerts a dose‐dependent inhibition of plasmin and kallikrein activities. Activation of these entities occurs ‘early’ in their respective pathways, and inhibition by aprotinin has downstream implications such as reducing the generation of thrombin, to minimize amplification of systems involved in the systemic inflammatory response. More localized effects of aprotinin at the level of the neutrophil, endothelial cell interaction or platelet‐thrombin interaction can have significant effects in terms of minimizing the damage to organs and tissues. The antiinflammatory effects associated with aprotinin treatment, in tandem with the hemostatic action, result in beneficial outcomes for many patients.
No takes yet. Share an insight, caveat, or question.
Kenneth M. Taylor (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: